ImmunityBio (IBRX) Return on Invested Capital (2015 - 2026)

ImmunityBio (IBRX) has 12 years of Return on Invested Capital data on file, last reported at 0.01% in Q1 2026.

• Return on Invested Capital for Q1 2026 came in at 0.01%, up 6.0% year-over-year; the trailing twelve-month figure through Mar 2026 was 0.01% (up 6.0% YoY), and the FY2025 annual result was 0.03%, changed N/A from the prior year.
• Return on Invested Capital advanced to 0.01% in Q1 2026 per IBRX's latest filing, from 0.01% in the prior quarter.
• Over five years, Return on Invested Capital peaked at 0.04% in Q2 2025 and troughed at 0.05% in Q1 2025.
• A 5-year average of 0.01% and a median of 0.01% in 2024 frame the typical range for Return on Invested Capital.
• The sharpest annual moves came in 2025 and 2026: Return on Invested Capital dropped 6 bps in 2025, then increased 6 bps in 2026.
• A 5-year view of Return on Invested Capital shows it stood at 0.01% in 2022, then climbed by 7 bps to 0.01% in 2023, then fell by 19 bps to 0.01% in 2024, then declined by 10 bps to 0.01% in 2025, then climbed by 2 bps to 0.01% in 2026.
• Business Quant data shows IBRX's Return on Invested Capital at 0.01% in Q1 2026, 0.01% in Q4 2025, and 0.01% in Q3 2025.